23:40 , Jul 7, 2017 |  BioCentury  |  Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
08:00 , Dec 6, 2010 |  BioCentury  |  Strategy

BTG's parallel worlds

Two years ago BTG plc took the first step toward becoming a specialty pharma by acquiring Protherics plc , an acute care company with two marketed products in the U.S. Now, BTG is adding a...
07:00 , Sep 6, 2010 |  BC Week In Review  |  Company News

BTG, Nycomed sales and marketing update

BTG said it will accelerate the reacquisition of U.S. marketing rights from Nycomed to CroFab , a polyclonal antibody against rattlesnake venom, and DigiFab , a polyclonal antibody against digoxin (digitalis) glycosides. BTG will regain...
08:00 , Dec 15, 2008 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/12 cls Arena (NASDAQ:ARNA) Fortis Patrick Moriarty Price target Buy 6% $3.83 UBS Jeff Elliott Price target Buy Moriarty lowered his target to $17...
07:00 , Sep 22, 2008 |  BC Week In Review  |  Company News

BTG, Protherics deal

BTG will acquire Protherics in a stock deal that values Protherics at £218.1 million ($393.3 million) or 60p per share. BTG said the deal price is a 46% premium to Protherics' close of 41.25p on...
07:00 , Sep 22, 2008 |  BioCentury  |  Finance

Shaking in their shorts

Shaking in their shortsA handful of heavily shorted small cap biotechs got a bounce last week after the U.S. Securities and Exchange Commission announced new actions intended to eliminate "naked" short selling - the abusive...
01:23 , Sep 19, 2008 |  BC Extra  |  Company News

BTG to acquire Protherics

BTG (LSE:BGC) will acquire Protherics (LSE:PTI; NASDAQ:PTIL) in a stock deal that values Protherics at L218.1 million ($393.3 million), or 60p per share. BTG said the deal price is a 46% premium to Protherics' close...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Company News

Protherics cardiovascular news

Protherics plc (LSE:PTI; NASDAQ:PTIL), London, U.K.   Business: Cardiovascular   Protherics is considering “approaches from a number of parties” interested in acquiring the company. Protherics has two marketed biologics in the U.S.: CroFab , a...
07:00 , Aug 18, 2008 |  BioCentury  |  Finance

Ebb & Flow

Investors reached new heights of optimism after a special committee of three independent Genentech board members rejected Roche ’s offer to buy the 44.1% of the biotech it doesn’t own for $89 a share, or...
00:12 , Aug 15, 2008 |  BC Extra  |  Financial News

Protherics gains on talk of acquisition

Protherics (LSE:PTI; NASDAQ:PTIL) gained 16.75p (44%) to 55p on Thursday after issuing a statement late Wednesday confirming that it has received "approaches from a number of parties" interested in acquiring the company. The stock gained...